Earnings summaries and quarterly performance for INSPERITY.
Executive leadership at INSPERITY.
Paul J. Sarvadi
Detailed
Chief Executive Officer
CEO
AS
A. Steve Arizpe
Detailed
President and Chief Operating Officer
CP
Christian P. Callens
Detailed
Senior Vice President of Legal, General Counsel and Secretary
JD
James D. Allison
Detailed
Executive Vice President of Finance, Chief Financial Officer and Treasurer
Board of directors at INSPERITY.
CR
Carol R. Kaufman
Detailed
Director
EJ
Eli Jones
Detailed
Director
EH
Ellen H. Masterson
Detailed
Director
JL
John L. Lumelleau
Detailed
Director
JM
John M. Morphy
Detailed
Director
LR
Latha Ramchand
Detailed
Director
RG
Richard G. Rawson
Detailed
Director
TT
Timothy T. Clifford
Detailed
Lead Independent Director
WP
W. Philip Wilmington
Detailed
Director
RM
Randall Mehl
Director
Research analysts who have asked questions during INSPERITY earnings calls.
AN
Andrew Nicholas
William Blair & Company
6 questions for NSP
Also covers: AMTD, CBZ, CLVT +16 more
JM
Jeff Martin
ROTH Capital Partners
6 questions for NSP
Also covers: BBSI, BGSF, BWMN +6 more
MM
Mark Marcon
Baird
6 questions for NSP
Also covers: ADP, AMN, ASGN +13 more
AP
Andrew Polkowitz
J.P. Morgan
5 questions for NSP
Also covers: ALIT, PAY, TNET
Tobey Sommer
Truist Securities, Inc.
5 questions for NSP
Also covers: AMN, AMTM, ASGN +26 more
AS
Andrew Steinerman
JPMorgan Chase & Co.
1 question for NSP
Also covers: ARMK, BFAM, CTAS +16 more
Jasper Bibb
Truist Securities
1 question for NSP
Also covers: ABM, AMN, APEI +15 more
Recent press releases and 8-K filings for NSP.
Insperity Reports Q4 2025 Results and Provides 2026 Outlook
NSP
Earnings
Guidance Update
Product Launch
- Insperity reported a challenging 2025, with Adjusted EBITDA declining 51% to $131 million and Adjusted EPS declining 71% to $1.03, primarily due to macroeconomic uncertainty and elevated healthcare claim costs.
- For 2026, the company projects significant recovery, forecasting full-year Adjusted EBITDA between $170 million and $230 million (an increase of 30%-76%) and Adjusted EPS between $1.69 and $2.72 (an increase of 64%-164%).
- Average paid worksite employees are expected to range from a 1.5% decline to a 1.5% increase in 2026 compared to 2025, with Q1 2026 projected at 303,000-305,000.
- Insperity is launching HRScale, a new PEO solution for mid-market clients, with beta clients going live by April 1st, 2026, and an expectation of 6,000-8,000 paid worksite employees on the platform by year-end 2026.
- Strategic initiatives for 2026 include continued margin recovery efforts through increased pricing (average in the teens), client selection, renegotiated healthcare contracts, and a 4% reduction in non-sales headcount expected to reduce operating expenses by $20 million.
Feb 10, 2026, 10:00 PM
Insperity Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance
NSP
Earnings
Guidance Update
New Projects/Investments
- Insperity reported Q4 2025 Adjusted EPS of -$0.60 (or -$0.54 excluding sales office consolidation expense) and Adjusted EBITDA of -$13 million (or -$11 million excluding sales office consolidation expense). For the full year 2025, Adjusted EBITDA declined 51% to $131 million and Adjusted EPS declined 71% to $1.03.
- The company forecasts full-year 2026 Adjusted EBITDA in the range of $170 million-$230 million and Adjusted EPS in the range of $1.69-$2.72. Average paid worksite employees for 2026 are projected to be between -1.5% and +1.5%.
- To address challenges from 2025, Insperity implemented margin recovery strategies, including increased pricing, renegotiated healthcare contracts, and a 4% reduction in non-sales headcount expected to save $20 million in operating expenses in 2026.
- Insperity is advancing its HRScale solution, a joint offering with Workday, with beta clients scheduled to go live in March and run payroll by April 1st, expecting 6,000-8,000 paid worksite employees on HRScale by year-end 2026.
- In 2025, Insperity returned capital to shareholders, paying $90 million in cash dividends and repurchasing 232,000 shares for $19 million. The company also amended its credit facility, increasing borrowing capacity to $750 million.
Feb 10, 2026, 10:00 PM
Insperity Reports Q4 2025 Results and Provides 2026 Outlook
NSP
Earnings
Guidance Update
New Projects/Investments
- For the full year 2025, Insperity's average number of worksite employees paid increased 1% to just over 310,000, while Adjusted EBITDA declined 51% to $131 million and Adjusted EPS declined 71% to $1.03. The company faced significant challenges from macroeconomic uncertainty in the small and medium-sized business market and elevated healthcare claim costs.
- For 2026, Insperity forecasts average paid worksite employees to be in a range of -1.5% to +1.5% compared to 2025. Full-year Adjusted EBITDA is projected between $170 million and $230 million, an increase of 30%-76%, and Adjusted EPS is forecasted between $1.69 and $2.72, an increase of 64%-164%.
- The company initiated an organizational realignment impacting approximately 4% of non-sales staff, expected to reduce operating expenses by $20 million in 2026. This is part of a broader strategy to enhance margin recovery through improved client selection and pricing.
- The HRScale solution, a joint offering with Workday for mid-market companies, is on track, with beta clients scheduled to go live and run payroll as of April 1st. This initiative is expected to be a new driver for large client sales and retention, significantly increasing the total addressable market.
Feb 10, 2026, 10:00 PM
Insperity Announces Fourth Quarter and Full Year 2025 Results
NSP
Earnings
Guidance Update
Share Buyback
- Insperity reported a net loss of $33 million and diluted EPS of $(0.88) for Q4 2025, with adjusted EBITDA at $(13) million.
- For the full year 2025, the company recorded a net loss of $7 million and diluted EPS of $(0.19), with adjusted EBITDA of $131 million.
- Revenues increased 3% in Q4 2025 and 4% for the full year 2025, reaching $6.8 billion.
- The company returned $109 million to shareholders during 2025, comprising $19 million for share repurchases and $90 million in cash dividends.
- Insperity provided full-year 2026 guidance with Adjusted EPS projected between $1.69 and $2.72 and Adjusted EBITDA between $170 million and $230 million, expecting a significant recovery in profitability.
Feb 10, 2026, 9:46 PM
Insperity Announces Fourth Quarter and Full Year 2025 Results and 2026 Guidance
NSP
Earnings
Guidance Update
Share Buyback
- Insperity reported a net loss of $7 million and adjusted EPS of $1.03 for the full year 2025, with revenues increasing 4% to $6.8 billion.
- In Q4 2025, the company recorded a net loss of $33 million and adjusted EPS of $(0.60), as revenues grew 3% year-over-year.
- The average number of worksite employees (WSEEs) paid per month increased 1% for both Q4 2025 (to 312,377) and the full year 2025 (to 310,089).
- The company returned $109 million to shareholders in 2025, including $19 million for share repurchases and $90 million in cash dividends.
- For 2026, Insperity projects full-year adjusted EPS to be between $1.69 and $2.72 and adjusted EBITDA between $170 million and $230 million.
Feb 10, 2026, 9:30 PM
Insperity Reports Q3 2025 Results and Outlines 2026 Rebound Plan
NSP
Earnings
Guidance Update
Product Launch
- Insperity (NSP) reported Q3 2025 adjusted EPS of minus $0.20 and adjusted EBITDA of $10 million, which fell below forecasted ranges primarily due to higher-than-expected benefits costs.
- The company updated its full-year 2025 guidance, forecasting adjusted EPS between $0.84 and $1.47 and adjusted EBITDA between $119 million and $153 million, with Q4 2025 adjusted EPS projected at minus $0.79 to minus $0.16.
- To address elevated healthcare claim costs, NSP has implemented higher pricing targets and extended its contract with UnitedHealthcare through 2028, which is expected to significantly reduce claim costs and lower the pooling level to $500,000 in 2026.
- The rollout of the new HR Scale solution, a joint offering with Workday, is underway with beta clients expected to go live in March 2026, anticipated to be a significant growth catalyst for worksite employees and revenue.
- Insperity expects a significant profitability rebound in 2026, aiming to recover a majority of the earnings shortfall experienced in 2025.
Nov 3, 2025, 10:00 PM
Insperity Reports Q3 2025 Earnings Decline and Provides FY 2025 Outlook
NSP
Earnings
Guidance Update
Profit Warning
- Insperity reported a significant decline in Q3 2025 Adjusted EBITDA to $10 million and Adjusted EPS to $(0.20), primarily due to higher-than-expected benefits costs driven by elevated inpatient, outpatient, and pharmacy trends, and increased frequency of large claim activity.
- The company's FY 2025 Adjusted EPS outlook is $0.84 - $1.47 and Adjusted EBITDA outlook is $119 - $153 million, reflecting a substantial year-over-year decrease largely due to the increased annual benefits cost trend.
- Management is implementing actions to drive profitability recovery in 2026, including renegotiating health insurance contracts, adjusting client pricing, and modifying claims pooling levels, in response to the unexpected step up in benefits costs experienced in 2025.
- Insperity launched HRScale, a strategic joint offering with Workday, in Q3 2025, which is expected to be a new catalyst for future growth, alongside strong Q3 sales performance for its flagship HR360 service.
- The company returned $87 million to shareholders through dividends and share repurchases during the first nine months of 2025.
Nov 3, 2025, 10:00 PM
Insperity Announces Q3 2025 Results, UnitedHealthcare Contract Extension, and Updated 2025 Guidance
NSP
Earnings
Guidance Update
Product Launch
- Insperity reported a net loss of $20 million and diluted EPS of $(0.53) for Q3 2025, with revenues increasing 4% year-over-year to $1.6 billion. Adjusted EBITDA was $10 million and adjusted EPS was $(0.20) for the quarter.
- The company announced the extension of its UnitedHealthcare contract through 2028, which is expected to provide significant cost savings and reduce the pooling level for large claims to $500,000 starting January 1, 2026.
- Insperity updated its 2025 guidance, projecting full-year adjusted EPS between $0.84 and $1.47 and adjusted EBITDA between $119 million and $153 million.
- Insperity is also rolling out HRScale, a strategic joint solution with Workday, which is expected to serve as a catalyst for future growth.
Nov 3, 2025, 9:45 PM
Insperity Reports Q3 Results, New UnitedHealthcare Contract, and Updates 2025 Guidance
NSP
Earnings
Guidance Update
New Projects/Investments
- Insperity reported a net loss of $20 million and diluted EPS of $(0.53) for Q3 2025, with revenues increasing 4% year-over-year to $1.6 billion.
- The company extended its contract with UnitedHealthcare through 2028, which is expected to provide significant cost reductions and lower risk starting January 1, 2026, and is rolling out its new HRScale product.
- Insperity updated its Full Year 2025 Adjusted EPS guidance to $0.84 - $1.47 and Adjusted EBITDA guidance to $119 million - $153 million.
- Year-to-date 2025, the company returned $87 million to shareholders, including $19 million for share repurchases and $68 million in cash dividends.
Nov 3, 2025, 9:30 PM
Insperity under investigation by law firm following Q2 2025 financial results
NSP
Legal Proceedings
Profit Warning
Guidance Update
- Bragar Eagel & Squire, P.C. is investigating Insperity, Inc. (NYSE:NSP) on behalf of its stockholders for potential violations of federal securities laws and/or unlawful business practices.
- This investigation follows Insperity's Q2 2025 financial results, announced on August 1, 2025, where the company reported adjusted earnings per share of only $0.26, missing analyst estimates and representing a 70% year-over-year decline.
- Insperity attributed these results to higher-than-expected benefits costs, specifically rising pharmacy expenses and an increased frequency of large insurance claims, and consequently lowered its full-year earnings forecast.
- On this news, Insperity's stock price fell $14.51 per share, or 24.35%, to close at $45.07 per share on August 1, 2025.
- Investors who suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. to discuss their legal rights.
Aug 31, 2025, 12:49 PM
Quarterly earnings call transcripts for INSPERITY.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more